Chugai Pharmaceutical Co., Ltd. (CHGCF) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - General Branche. Der Hauptsitz des Unternehmens ist in Chuo, Japan. Der aktuelle CEO ist Osamu Okuda.
CHGCF hat IPO-Datum 2012-08-03, 5,026 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $90.63B.
Chugai Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacture, and sale of medicines globally. The company maintains a diverse portfolio spanning oncology, immunology, hematology, ophthalmology, and other therapeutic areas, with established products including Tecentriq, Herceptin, Avastin, Rituxan, and Tamiflu. As a subsidiary of Roche Holding Ltd., Chugai leverages strategic alliances within the Roche Group and conducts collaborative research with academic institutions to advance its pipeline of development candidates. Founded in 1925 and headquartered in Chuo, Japan, the company continues to expand its international presence across multiple disease indications.
